CYTARZER 500MG

Cytarzer – 500 IP

Composition: Cytarabine IP – 500 mg (For intrathecal, intravenous, and subcutaneous administration)

Therapeutic Class: Antimetabolite

Cytarzer 500 Aprazer’s trusted and affordable oncology solution, with the best quality and efficacy, improves overall survival rates for AML patients.

Cytarzer: Advancing AML Care, Globally

With a commitment to accessible healthcare for all, Aprazer Healthcare brings hope to AML patients by ensuring affordable Cytarzer to meet the rising demand in Southeast Asian countries and other developing nations with aging populations.
WHO- GMP certified, assured therapeutic efficacy and safety.

Uses of Cytarzer 500

Cytarabine 500 is used to treat advanced cancers- short infusion /bolus.

• • Advanced-stage Acute Myeloid Leukemia (AML)
• • Post-remission therapy (consolidation, relapse/refractory AML)
• • High-dose drug regimens
• • For aggressive treatment or relapse control
• • Patients requiring aggressive treatments or relapse control.

Other uses:

Besides leukemia, it’s widely used for various types of Lymphomas.

How does Cytarzer work?

Cytarabine works by inhibiting DNA repair and multiplication.

Common Side Effects

• • Low blood count
• • Diarrhea
• • Constipation
• • Alopecia (Hair loss)
• • Abdominal pain
• • Mouth sores
• • Skin rashes
• • Risk of infections
• • Weakness

Toxicities

• • Neurotoxicity – confusion, seizures
• • Ocular toxicity – blurred vision
• • Bone marrow suppression – bleeding
• • Hepatotoxicity – elevated liver enzymes

Precautions

To be used cautiously in patients with:

• • Pre-existing liver dysfunction
• • Renal dysfunction
• • Immune-compromised patients
• • HIV co-infections
• • Neurological disorders

Contraindications

• • Not to be used if any previous allergy or hypersensitivity to Cytarabine or any excipients.
• • Breastfeeding mothers
• • Pregnant women

Warning

To be used under the supervision of a qualified medical practitioner or oncology specialist with access to appropriate diagnostic and monitoring facilities.

Important Safety and Monitoring Information

Regular monitoring of neurological conditions, total blood count, ocular function, infection risk, hepatic functions, and renal functions.

Storage

It should be stored at 2-8 degrees Celsius, protected from light.

Administration Instructions

• • To be administered intrathecal, subcutaneous, or as a slow IV infusion.
• • To be used immediately after reconstitution.